SANUWAVE Announces Positive 24-Week Data from Pivotal Trial. Print E-mail
By Staff and Wire Reports   
Tuesday, 12 July 2011 19:43
Below is a look at some of the headlines for companies that made news in the healthcare sector on July 12, 2011.

SANUWAVE Health, Inc. (OTC:SNWV), announced positive 24-week data from its pivotal double-blinded, randomized Phase III, Investigational Device Exemption (IDE) clinical trial comparing dermaPACE with Sham-control (non-active treatment), when both are combined with the current standard of care for the treatment of diabetic foot ulcers. Diabetic foot ulcers are an area of significant unmet medical need.

The 206-patient, randomized, double-blinded, parallel-group, sham-controlled, multicenter, 24-week pivotal clinical trial was designed to quantify the safety and effectiveness of four, 20-minute, noninvasive procedures with dermaPACE, delivered over a two-week period.

The primary efficacy endpoint of complete wound closure reached statistical significance at 20 weeks in the Intent-to-Treat (ITT) population with 36% of dermaPACE subjects achieving complete wound closure compared with 23% of Sham-control subjects (p=0.047); in the Efficacy Evaluable (EE) population 38% of dermaPACE subjects achieved complete wound closure beginning at 20 weeks, compared with 21% of Sham-control subjects (p=0.018); at 24 weeks dermaPACE achieved 40% complete wound closure in the ITT population (p=0.054) and 41% complete wound closure in the EE population (p=0.022).

Subjects treated with dermaPACE achieved a significant increase in the rate of complete wound closure or ≥90% wound area reduction by or at 12 weeks (p=0.016).


Also Tuesday:


Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)
(the "Company") today announced that the European Patent Office ("EPO") has granted a patent for the use of alkyl phosphocholines, more specifically perifosine (octadecyl 1,1-dimethylpiperidino-4-yl phosphate), in the preparation of a medicament for the treatment of benign and malignant tumours, prior to and/or during the treatment with approved anti-tumour anti-metabolites such as 5FU ("fluorouracil") and capecitabine.

Amarantus BioSciences (OTCBB: AMBS), a California-based biotechnology company developing a first-in-class anti-apoptosis therapeutic protein known as MANF, and Generex Biotechnology, Inc. (OTCBB: GNBT), a Toronto-based biotechnology company developing an oral-insulin spray technology known as Oral-lyn™ currently in Phase III clinical trials, today announced that the companies have selected the development of a MANF-based therapeutic for the treatment of the beta cell destruction at the root of diabetes as the second program for their joint research collaboration announced on May 31, 2011.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced today results from a Phase 1 clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor which is intended for the treatment of pulmonary arterial hypertension, or PAH.

BioElectronics Corp. (OTCQB: BIEL) (PINKSHEETS: BIEL)
, the maker of topical drug-free pain relievers, is pleased to announce that Greenwood Group, consumer packaged goods brand management experts, have added its ActiPatch® musculoskeletal pain therapy, and Allay™ menstrual pain therapy products to their retail products portfolio.

Boston Scientific Corporation (NYSE:BSX) has completed patient enrollment in the ASTI post-market clinical follow-up study designed to evaluate its Adapt™ Monorail™ Carotid Stent System in combination with its FilterWire EZ™ Embolic Protection System for treatment of carotid artery disease in patients at high risk for carotid surgery.

Cardio Infrared Technologies, Inc. (PINKSHEETS: CDOI) www.cardioinfraredtech.com, www.thebiofit.com, a leading Health and Wellness technology and marketing company, announced today that Cardio Infrared Technologies, Inc. is negotiating with two national fitness centers that would provide an exclusive relationship with each gym for a period of four years.

Cytori Therapeutics (NASDAQ: CYTX) entered into an equity purchase agreement with Seaside 88, LP ('Seaside').

General Cannabis, Inc. (PINKSHEETS: CANA)
, a technology-based Internet marketing services company, today announced that its website WeedMaps.com reported record revenue of more than $1.0 million for the month ended June 30, 2011.

Healthnostics, Inc. (PINKSHEETS: HNSS) has received an offer to purchase the Company for $.01 per share.

Life Technologies Corporation (NASDAQ:LIFE), a provider of innovative life science solutions, today introduced the first USDA-approved, real-time PCR test to detect a broad range of Swine Influenza Virus (SIV), a common debilitating condition that causes fever, lethargy, breathing problems and significant weight loss resulting in economic loss to producers.

Medical Marijuana Inc (PINKSHEETS: MJNA) is pleased to announce that as of July 12, the company has made substantial progress towards achieving fully-reporting status.

The following blog by Bob Lorsch, CEO of MMRGlobal, Inc. (OTCBB: MMRF), was picked up today and is available at http://blog.mmrglobal.com: "Every person, all the events of your life, are there because you have drawn them there. What you choose to do with them is up to you."

mPhase Technologies, Inc. (OTCBB: XDSL)
held a Special Meeting of Shareholders on Wednesday, June 29, 2011 at 10:00 A.M. at 587 Connecticut Avenue, Norwalk, Ct. 06854.

Panacea Global, Inc., (OTCQB: PANG), a biopharmaceutical company specializing in blood (protein), serum and tissue tests to diagnose and monitor cancer, today announced that it has signed a multi-year exclusive sales agreement with Palmverse Limited for its cancer detection system.

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Caliper Life Sciences, Inc. (NASDAQ:CALP) today announced a co-marketing agreement for the development and optimization of automated protocols for the NimbleGen SeqCap EZ Library solution-based capture method for Caliper's Sciclone® NGS Workstation.  

Trinity Biotech plc (NASDAQ:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter of fiscal year 2011 on Thursday, July 21, 2011.

Verisante Technology, Inc. (TSX VENTURE:VRS) (OTCQX:VRSEF) (PINK SHEETS:VRSEF) (the "Company" or "Verisante"), a leader in cancer imaging technology, is pleased to announce that it has entered into an agreement to license the exclusive world-wide rights for a novel rapid multi-spectral imaging cancer detection technology with the inventors, Dr. Haishan Zeng and Dr. Yasser Fawzy of the British Columbia Cancer Agency.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter